Researcher.Life Logo

The Lancet Oncology : Impact Factor & More

eISSN: 1474-5488pISSN: 1470-2045

Key Metrics

CiteScore
56.9
Eigenfactor
0.1 - 0.5
H-Index
382
Impact Factor
>= 25
Scite Index
0.86 5-Year SI
SJR
Q1Oncology
SNIP
11.42
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on The Lancet Oncology

The Lancet Oncology Journal Specifications

Overview
Publisher ELSEVIER SCIENCE INC
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2000
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in The Lancet Oncology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in The Lancet Oncology

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.
  • 1 Jul 2026
  • The Lancet. Oncology
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
  • 1 Jul 2026
  • The Lancet. Oncology
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
  • 1 Jul 2026
  • The Lancet. Oncology
Delivering transformational change for patients and the environment through England's National Cancer Plan.
  • 1 Jul 2026
  • The Lancet. Oncology
Preliminary results from PRIMARY2: bringing colour to a grey arena.
  • 1 Jul 2026
  • The Lancet. Oncology
Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
  • 1 Jul 2026
  • The Lancet. Oncology
European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.
  • 1 Jul 2026
  • The Lancet. Oncology
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
  • 1 Jul 2026
  • The Lancet. Oncology
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
  • 1 Jul 2026
  • The Lancet. Oncology
Delivering transformational change for patients and the environment through England's National Cancer Plan.
  • 1 Jul 2026
  • The Lancet. Oncology
Preliminary results from PRIMARY2: bringing colour to a grey arena.
  • 1 Jul 2026
  • The Lancet. Oncology
Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.
  • 1 Jul 2026
  • The Lancet. Oncology

FAQs on The Lancet Oncology